Weight
Orforglipron
Metabolic
35
Amino acids
Molecular weight
Peptide
Type
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Top researched benefits
Overview of Orforglipron
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
Weight Loss
- ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
- ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
- 91% achieved near-normal blood sugar levels versus 42% with placebo.
Type 2 Diabetes
- ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
- Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Storage
Room temperature 15-30°C; no refrigeration needed
Frequency
Once daily oral tablet
Typical Dose
Start 3-6mg daily, titrate up to 12-36mg based on response
Cycle Duration
Long-term continuous therapy (72+ weeks in trials)
Chemical Makeup
Key benefits
Significant weight loss (up to 12.4% at 72 weeks)
Robust diabetes control (HbA1c reduction 1.3-1.6%)
Once-daily oral tablet format
No refrigeration or food restrictions required
Reduced cardiovascular risk markers
Community interest
This peptide is still gaining traction in the community.
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesOrforglipron Molecular Information
View the scientifc details of Orforglipron.
35
Amino Acids
Orforglipron
Asn
Asn
Position 1
Pyl
Pyl
Position 2
Thr
Thr
Position 3
Ala
Ala
Position 4
Pro
Pro
Position 5
Pro
Pro
Position 6
Leu
Leu
Position 7
Ile
Ile
Position 8
Cys
Cys
Position 9
Ala
Ala
Position 10
Asx
Asx
Position 11
Leu
Leu
Position 12
Glu
Glu
Position 13
Ser
Ser
Position 14
Tyr
Tyr
Position 15
Asn
Asn
Position 16
Thr
Thr
Position 17
His
His
Position 18
Glu
Glu
Position 19
Thr
Thr
Position 20
Ile
Ile
Position 21
Cys
Cys
Position 22
Ser
Ser
Position 23
Met
Met
Position 24
Ala
Ala
Position 25
Leu
Leu
Position 26
Leu
Leu
Position 27
Met
Met
Position 28
Pyl
Pyl
Position 29
Leu
Leu
Position 30
Glu
Glu
Position 31
Cys
Cys
Position 32
Sec
Sec
Position 33
Leu
Leu
Position 34
Glu
Glu
Position 35
Molecular Weight
882.974DaChain Length
35Amino AcidsType
PeptideOrforglipron Protocols
Once-daily oral tablet requiring no reconstitution. Can be taken with or without food or water at any time of day.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Type 2 diabetes initiation | 3 | 1 week range | Oral tablet |
| Type 2 diabetes moderate control | 12 | 1 week range | Oral tablet |
| Type 2 diabetes optimal control | 36 | 1 week range | Oral tablet |
| Weight loss initiation | 6 | 1 week range | Oral tablet |
| Weight loss optimization | 36 | 1 week range | Oral tablet |
Orforglipron Cycle
The Orforglipron Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Appetite reduction typically within 1-3 days; mild to moderate nausea common
- Week 2-4
- Gradual weight loss begins (0.5-2 lbs per week); improved blood sugar control
- Week 4-12
- Reduced food cravings; GI adverse effects generally diminish; metabolic markers improving
- Week 12-36
- Continued progressive weight loss without plateau
- Week 0-0
- Long-term therapy well-tolerated; sustained benefits at 72 weeks
Dosing tools
Orforglipron Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
Orforglipron
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Orforglipron vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- Orforglipron
- Dosing
- Start 3-6mg daily, titrate up to 12-36mg based on response
- Dosing Frequency
- Once daily oral tablet
- Cycle Duration
- Long-term continuous therapy (72+ weeks in trials)
- Storage
- Room temperature 15-30°C; no refrigeration needed
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Orforglipron interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
No known interactions; may support gut health and potentially mitigate GI adverse effects.
Weight
sem
Metabolic
Semaglutide
AVOID
Both are GLP-1 agonists; combining increases severe hypoglycemia and excessive GI adverse effects.
Weight
tir
Metabolic
Tirzepatide
AVOID
Dual GIP/GLP-1 agonist overlaps with GLP-1 mechanism; combination contraindicated.
Side effects
Avoid: Do not take Orforglipron with Semaglutide, Tirzepatide.
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Stop signs
Severe or persistent abdominal pain radiating to back (potential pancreatitis)
Neck lumps, hoarseness, difficulty swallowing, or neck swelling
Severe nausea/vomiting preventing adequate nutrition or hydration
Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
Suicidal thoughts, severe depression, or significant mood changes
Vision changes or persistent eye pain
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
OrforglipronResearch References
Orforglipron is an extensively studied compound
Orforglipron
Orforglipron is an extensively studied compound
ATTAIN-1 Phase 3 Trial (Obesity)
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
2025
ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
2025
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
2025
Phase 2 Obesity Study
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
2023